Literature DB >> 23942919

Overcoming obstacles in accessing unfunded oral chemotherapy: physician experience and challenges.

Dolly Han1, Martina Trinkaus, Sophie Hogeveen, Muhammad Mamdani, Scott R Berry, Raymond W Jang, Jeffrey S Hoch, Christine Simmons.   

Abstract

PURPOSE: Previous studies have shown hematologists and medical oncologists may not accept the financial limits set by governing agencies on patient access to oral chemotherapy. The purpose of this study was to capture the methods physicians used to overcome barriers to accessing chemotherapeutic regimens for their patients.
METHODS: A total of 640 medical oncologists and hematologists across Canada were surveyed using a 13-item Web-based survey tool. The survey was delivered by e-mail with three follow-up reminders. After a response period of 3 months, results were collated and analyzed with descriptive statistics.
RESULTS: Of the 640 invitations, 568 were successfully delivered, and 183 responses were received (response rate, 32.0%). Among respondents, 101 treated solid malignancies (55.2%), 49 treated nonsolid malignancies (26.8%), and 33 treated both (18.0%). To overcome funding barriers, participating oncologists enrolled patients onto clinical trials (90.5%), used compassionate access programs (96.1%), and made special requests to government (91.8%). Other methods included writing false claims on forms to fit funding criteria for drugs (31.1%) and using leftover drug supplies (31.0%). Physicians felt their inability to obtain unfunded medications had a negative impact on their patients' clinical outcomes (56.0%) and psychosocial quality of life (73.0%). Only 28.5% of physicians contacted their governing body with concerns about oral chemotherapy funding.
CONCLUSION: Canadian physicians use numerous methods to obtain unfunded oral chemotherapies, including falsifying claims on access forms and submitting special requests to government agencies. Further study is warranted to explore the disconnection between policymakers and physicians with regard to funding of oral chemotherapies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23942919      PMCID: PMC3710167          DOI: 10.1200/JOP.2012.000680

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


  13 in total

1.  Access to cancer drugs in Canada: looking beyond coverage decisions.

Authors:  Roger Chafe; Anthony Culyer; Mark Dobrow; Peter C Coyte; Carol Sawka; Susan O'Reilly; Kara Laing; Maureen Trudeau; Sharon Smith; Jeffrey S Hoch; Steve Morgan; Stuart Peacock; Rick Abbott; Terrence Sullivan
Journal:  Healthc Policy       Date:  2011-02

2.  Toward higher-performance health systems: adults' health care experiences in seven countries, 2007.

Authors:  Cathy Schoen; Robin Osborn; Michelle M Doty; Meghan Bishop; Jordon Peugh; Nandita Murukutla
Journal:  Health Aff (Millwood)       Date:  2007 Nov-Dec       Impact factor: 6.301

3.  Do oncologists discuss expensive anti-cancer drugs with their patients?

Authors:  J Thomson; P Schofield; L Mileshkin; E Agalianos; J Savulescu; J Zalcberg; M Jefford
Journal:  Ann Oncol       Date:  2006-01-17       Impact factor: 32.976

Review 4.  Adherence to therapy with oral antineoplastic agents.

Authors:  Ann H Partridge; Jerry Avorn; Philip S Wang; Eric P Winer
Journal:  J Natl Cancer Inst       Date:  2002-05-01       Impact factor: 13.506

5.  To tell or not to tell: the community wants to know about expensive anticancer drugs as a potential treatment option.

Authors:  Linda Mileshkin; Penelope E Schofield; Michael Jefford; Emilia Agalianos; Michele Levine; Alan Herschtal; Julian Savulescu; Jacqui Ann Thomson; John R Zalcberg
Journal:  J Clin Oncol       Date:  2009-09-28       Impact factor: 44.544

Review 6.  A changing paradigm for cancer treatment: the advent of new oral chemotherapy agents.

Authors:  Cindi Holt Bedell
Journal:  Clin J Oncol Nurs       Date:  2003 Nov-Dec       Impact factor: 1.027

Review 7.  Patient education: the cornerstone of successful oral chemotherapy treatment.

Authors:  Kristine Hartigan
Journal:  Clin J Oncol Nurs       Date:  2003 Nov-Dec       Impact factor: 1.027

8.  Do oncologists believe new cancer drugs offer good value?

Authors:  Eric Nadler; Ben Eckert; Peter J Neumann
Journal:  Oncologist       Date:  2006-02

Review 9.  External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer.

Authors:  Christopher M Booth; George Dranitsaris; M Corona Gainford; Scott Berry; Michael Fralick; John Fralick; Joanna Sue; Mark Clemons
Journal:  BMC Cancer       Date:  2007-06-28       Impact factor: 4.430

Review 10.  Oral cancer treatment: developments in chemotherapy and beyond.

Authors:  V J O'Neill; C J Twelves
Journal:  Br J Cancer       Date:  2002-10-21       Impact factor: 7.640

View more
  2 in total

1.  Current Attitudes toward Unfunded Cancer Therapies among Canadian Medical Oncologists.

Authors:  Selina K Wong; Lovedeep Gondara; Sharlene Gill
Journal:  Curr Oncol       Date:  2021-11-16       Impact factor: 3.677

Review 2.  Not All Canadian Cancer Patients Are Equal-Disparities in Public Cancer Drug Funding across Canada.

Authors:  Ceilidh MacPhail; Stephanie Snow
Journal:  Curr Oncol       Date:  2022-03-17       Impact factor: 3.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.